MR lymphangiography (MRL) utilizing the clinically available small molecular weight gadolinium contrast agents suffers from diffusion of contrast out of the lymphatic system and into the blood pool. We describe a modified MRL technique where a clinically available iron oxide nanoparticle (ferumoxytol) is used as the lymphatic contrast agent. The higher molecular weight of these nanoparticles results in retention of contrast within the lymphatic system. This simplifies peripheral lymphatic imaging by eliminating the need for vascular contamination suppression techniques and should allow better tracking of contrast through the central lymphatics following pedal injections.
This abstract and the presentation materials are available to members only; a login is required.